Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Publish Ahead of Print published online ahead of print October 12, 2007
DOI: 10.2337/db07-0838

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-0838v1
57/1/41    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blatnik, M.
Right arrow Articles by Baynes, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blatnik, M.
Right arrow Articles by Baynes, J. W.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Inactivation of Glyceraldehyde-3-Phosphate Dehydrogenase by Fumarate in Diabetes: Formation of S-(2-succinyl)cysteine, a Novel Chemical Modification of Protein and Possible Biomarker of Mitochondrial Stress

Matthew Blatnik1, Norma Frizzell1, Suzanne R. Thorpe1, and John W. Baynes1

1The Department of Chemistry and Biochemistry, University of South Carolina

Objective: S-(2-succinyl)cysteine (2SC) is formed by a Michael addition reaction between the Krebs cycle intermediate, fumarate, and cysteine residues in protein. We have investigated the role of fumarate in chemical modification and inhibition of the sulfhydryl enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), in vitro and in tissues of diabetic rats.

Research Design and Methods: GAPDH was incubated with fumarate in phosphate buffer to assess effects of fumarate on enzyme activity in vitro. Sites of 2SC formation were determined by analysis of tryptic peptides by HPLC-quadrupole-time of flight (QTOF) mass spectrometry (MS). 2SC and fumarate in gastrocnemius muscle of control and streptozotocin-induced diabetic rats were measured by LC/MS/MS and GC/MS, respectively. GAPDH was isolated from muscle by immunoprecipitation, and sites of modification of GAPDH were determined by MS analysis.

Results: 2SC was found, both in vitro and in vivo, about equally at active site Cys-149 and nucleophilic Cys-244. Inactivation of GAPDH by fumarate in vitro correlated with formation of 2SC. In diabetic compared to control rats, fumarate and 2SC concentration increased ~5-fold, accompanied by an ~25% decrease in GAPDH specific activity. The fractional modification of GAPDH by 2SC was significantly increased in diabetic vs. control animals, consistent with the decreased specific activity of GAPDH in muscle of diabetic animals.

Conclusion: Fumarate contributes to inactivation of GAPDH in diabetes. 2SC may be a useful biomarker of mitochondrial stress in diabetes. Modification of GAPDH and other enzymes and proteins by fumarate may contribute to the metabolic changes underlying the development of diabetic complications.


Correspondence: john.baynes{at}sc.edu


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.